INFORMATION DISCLOSURE **Application Number** 10/624,447 STATEMENT BY APPLICANT Filing Date July 21, 2003 **Tod Woolf** First Named Inventor 1632 **Group Art Unit** 1635 **Examiner Name** Unknown 089596-0502/INV850/4-16CONUS/55014) Sheet of **Attorney Docket U.S. PATENT DOCUMENTS** Examiner **Document Number** Publication Name of Patentee or Applicant of Cited Document Initials Cite No. Kind Code (if MM-DD-YYYY Number known) Name of Patentee or Applicant of Cited Document **Publication FOREIGN PATENT DOCUMENTS** Examiner Cite MM-DD-YYYY Initials No. Country Code Number Kind Code (if known) (Number 43) AMBION, INC. **B**1 WO 04/046320 6/3/2004 PCT **A2** AMBION, INC. **B2** WO 04/046320 **A3** 6/3/2004 **PCT** Examiner Date 11-20-06: Considered Signature

REV 7-80			PAIE	NT AND TRADEMARK OFFICE	SRI-004	ì	09/295,189		
PHSTO	F PUBLI	CATIONS	CITED BY	APPLICANT	APPLICANT				
し」 \	(Use several sheets if necessary				Tod M. Woolf		GROUP		
4 2003 N)				April 20, 1999		1635		
100 ALTH SEE			U.S	S. PATENT DOC	UMENTS				
DEMAN	DOCUA	KENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRI	DATE
								IF APPA	A-RIATE
				•					
			FORE	IGN PATENT DO	OCUMENTS			,	<u>.</u>
	DOCUA	MENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANS YES	LATION NO
+3°	' wo	91/17424	11/1991	PCT					
	****	95/18139	7/1995	PCT					
√ C	3 WO	98/13526	4/1998	PCT					
				<u> </u>		<u> </u>			
7 10	Alt				ite, Pertinent Pages Applied Antisense o		leotide Tech	nology (Stein:
342L					York, 1998) pp. 73-			\	•
41-7							-		
() d c.	Gr	øtli, Morten	et al. "2'-	O-Propargyl Oligo	oribonucleotides: Sy		d Hybridisal	tion"	
Ct	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 19-914 (May 28, 1 ng hydrophilic coi	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.
	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 9-914 (May 28, 1	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.
	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 19-914 (May 28, 1 ng hydrophilic coi	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.
	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 19-914 (May 28, 1 ng hydrophilic coi	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.
	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 19-914 (May 28, 1 ng hydrophilic coi	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.
	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 19-914 (May 28, 1 ng hydrophilic coi	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.
	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 19-914 (May 28, 1 ng hydrophilic coi	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.
	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 19-914 (May 28, 1 ng hydrophilic coi	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.
	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 19-914 (May 28, 1 ng hydrophilic coi	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.
	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 19-914 (May 28, 1 ng hydrophilic coi	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.
	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 19-914 (May 28, 1 ng hydrophilic coi	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.
	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 19-914 (May 28, 1 ng hydrophilic coi	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.
	Gr Te	øtli, Morten <i>trahedron t</i> ochiantz, A	et al. "2'- 54(22):589 lain "Gettir	O-Propargyl Oligo 19-914 (May 28, 1 ng hydrophilic con :629-34 (Oct. 199	oribonucleotides: Sy 1998) mpounds into cells:	nthesis an	•		Curr.

		•			
	APPLICANT FACSIMILE OF FORM PTO-1448 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO.	SERIAL NO.	
			SRI-004	09/295,189	
بالمسمور	D LIST OF PUBLICATIONS	CITED BY APPLICANT	APPLICANT		
/o'	Use several she	ets if necessary)	Tod M. Woolf		
	[FILING DATE	GROUP	
OCT	2 4 2003 2		April 20, 1999	16 31	
~·					

U.S. PATENT DOCUMENTS

114	DEM		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
5	12	AA	5,594,121	1/97	Froeher et al.	536	23.5	
	0	AB	5,830,653	11/98	Froehler et al.	435	6	
		AC	5,777,153	7/98	Lin et al.	560	158	
「		AD	5,955,589	9/99	Cook, et al.	536	23.1	

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

		OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)								
0-	AE	Dean, Nicholas M. and Griffey, Richard H. (1997) "Identification and Characterization of Second-Generation Antisense Oligonucleotides" Antisense & Nucleic Acid Drug Development Vol. 7 pp.								
25		229-233;								
	AF	Escude, Christophe et al. (1996) "Stable Triple Helices Formed by Oligonucleotide N3' →P5'								
		Phosphoramidates Inhibit Transcription Elongation" Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 4365-4369;								
+	AG .	Escude, Christophe et al. (1998) "Rational Design of a Triple Helix-Specific Interacalating								
		Ligand" Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3591-3596;								
	AH	Flanagan, W. Michael et al. (1999) "A Cytosine Analog That Confers Enhanced Potency To Antisense Oligonucleotides" Proc. Natl. Acad. Sci. USA, Vol. 96, pp. 3513-3518;								
	Al	Helene, Claude and Thuong, Nguyen T. (1989) "Control of Gene Expression by Oligonucleotides								
		Covalently Linked to Intercalating Agents" Genome, Vol. 31, pp. 413-421;								
	~	Giovannangeli, Carne and Helene, Claude (1997) "Progress In Developments of Triplex-Based Strategies" Antisense & Nucleic Acid Drug Development, Vol. 7, pp. 413-421;								
	AK	Gutierrez, Arondl J. et al. (1997) "Antisense Gene Inhibition by C-5-Substituted Deoxyuridine-Containing Oligodeoxynucleotides" Bicohemistry, Vol. 36, pp. 743-748;								
	AL	Hoke, Glenn D. et al. (1991) "Effects of Phosphorothioate Capping On Antisense Oligonucleotide								
		Stability, Hybridization and Antiviral Efficacy Versus Herpes Simplex Virus Infection" Nucleic Acids Research, Vol, 19, No. 20 pp. 5743-5748;								
	AM	Jarvis, Thale C. et al. (1996) "Optimizing The Cell Efficacy of Synthetic Ribozymes" The Journal								
		of Biological Chemistry, vol. 271, No. 46, pp. 29107-29112;								
	AN	Kukreti, Shrikant et al. (1997) "Extension of the Range of DNA Sequences Available For Triple Helix Formation: Stabilization of Mismatched Triplexes By Acridine-Containing Oligonucleotides", Nucleic Acids Research, Vol. 25, No. 21 pp. 4264-4270;								
1	AO	Lacoste, Jerome et al. (1997) "Triple Helix Formation With Purine-Rich Phosphorothioate-								
I		Containing Oligonucleotides Covalently Linked To an Acridine Derivatve" Nucleic Acids								
		Research, Vol. 25. No. 10 pp. 1991-1998;								
	AP	Lewis, Jason G. et al. (1996) "A Serum-Resistant Cytofectin For Cellular Delivery of Antisense Oligodeoxynucleotides And Plasmid DNA" Proc. Natl. Acad. Sci. USA, Vol 93, pp. 3176-3181;								
1	ΔQ	Marchand, Christophe et al. (1996) "Stabilization of Triple Helical DNA by A								
A)		Benzopyridoquinoxaline Intercalator" Biochemistry, Vol. 35, pp. 5022-5032;								
Examine	r (Date Considered								
		11-20-06								
*EXAMI	NER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

		•					Sheet 2 of 2	
APPLICANT FACSIM REV 7-80	ILE OF FORM PTO-1449		TMENT OF COMMERCE D TRADEMARK OFFICE	SRI-004	٠	SERIAL NO. 09/295, 18	19	
~ \	PUBLICATIONS (Use several shee			Tod M. Woolf	1			
m ?	(036 3646161 31166	to ii licoco	130, 3 ,	FILING DATE April 20, 1999		GROUP	1635	
- E			U.S. PATENT I				<u> </u>	
POTINER INITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	·							
				e, Date, Pertinent Pag				
3/3/8	Matteucci,		Wagner, Richa	rd W. (1996) "In Pursu	it of Antis	ense" Natur	'e, Vol. 384	
ВВ	Murine Prote	in Kinase (ed Activity of an Antisporation of 2'-O-Prop				
8C	Milligan, Johr	F. et al. (Concepts In Antisense	Drug De	sign" Journa	al of Medicinal	
BD	Moulds, Cour	tney et al.	(1995) "Site and	d Mechanism of Antis , pp. 5044-5053;	ense Inhib	oition By C-5	Propyne	
θE	Internucleotic	leic Linkag	o J. et al. (1992) "Antisense Effect of Oligodeoxynucleotides With Inverted Terminal eic Linkages: A Minimal Modification Protecting Against Nucleolytic Degradation" search And Development, Vol. 2, pp. 129-146;					
BF	Stein, C.A. ar	nd Cheng,	Y.C. (1993) "An	itisense Oligonucleotion, pp. 1004-1012;	des As Th	erapeutic A	gents - Is the	
8G				sense Gene Inhibition 0, pp. 1510-1513;	by Oligon	ucleotides C	ontaining C-5	
ВН				nt and Selective Inhib technology, Vol. 14, p			ion By an	
BI				riple-Helix Specific Intery, Vol. 32, pp. 10614-		As Antigene	e Enhancers:	
		······································						
							No. of Street,	
								
Examiner	Q 2			Date Considered	-)(06	<u> </u>	
*EXAMINER:		f not in confo		not citation is in conformal sidered. Include copy of the	nce with MP	EP 609; Draw		